Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

Abstract Background Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2-negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line chemotherapy and the characteristics of the...

Full description

Bibliographic Details
Main Authors: Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Cancer
Subjects:
Advanced breast cancer
Eribulin
HER2-negative
Overall survival
Real world
Online Access:https://doi.org/10.1186/s12885-021-09137-0

Similar Items

Similar Items